ArticleeLife2020
Reducing respiratory syncytial virus (RSV) hospitalization in a lower-income country by vaccinating mothers-to-be and their households.
Article in eLife, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Mathematical modelling of respiratory syncytial virus (RSV) in low- and middle-income countries: A systematic review.Epidemics · 2021Pooled it
- Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods and Input Data.PharmacoEconomics · 2021Pooled it
- The influence of age-dependent susceptibility on RSV transmission dynamics and immunisation population-level impact.BMC medicine · 2026Article
- Maternal RSV immunization: clinical efficacy, immunological mechanisms and public health implications for preventing infant lower respiratory tract infection.Journal of health, population, and nutrition · 2026Review
- Identifying climatic drivers of respiratory syncytial virus (RSV) seasonality in Antananarivo, Madagascar, 2011-2021: a sentinel surveillance study.BMJ public health · 2024Article
- The Impact of Coronavirus Disease 2019 on Viral, Bacterial, and Fungal Respiratory Infections.Clinics in chest medicine · 2023Review
- Estimates of the national burden of respiratory syncytial virus in Kenyan children aged under 5 years, 2010-2018.BMC medicine · 2023Article
- The Impact of Maternal Human Immunodeficiency Virus Infection on the Burden of Respiratory Syncytial Virus Among Pregnant Women and Their Infants, Western Kenya.The Journal of infectious diseases · 2022Article
- Challenges in Maximizing Impacts of Preventive Strategies against Respiratory Syncytial Virus (RSV) Disease in Young Children.The Yale journal of biology and medicine · 2022Review
- Use of mathematical modelling to assess respiratory syncytial virus epidemiology and interventions: a literature review.Journal of mathematical biology · 2022Review
- RSV Prevention in All Infants: Which Is the Most Preferable Strategy?Frontiers in immunology · 2022Review
- Integrating epidemiological and genetic data with different sampling intensities into a dynamic model of respiratory syncytial virus transmission.Scientific reports · 2021Article
- Modelling the household-level impact of a maternal respiratory syncytial virus (RSV) vaccine in a high-income setting.BMC medicine · 2020Article
- Estimating Transmission Parameters for Respiratory Syncytial Virus and Predicting the Impact of Maternal and Pediatric Vaccination.The Journal of infectious diseases · 2020Article
- The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models.Vaccine · 2020Article
- Model evaluation of target product profiles of an infant vaccine against respiratory syncytial virus (RSV) in a developed country setting.Vaccine: X · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Respiratory syncytial virus is the leading cause of lower respiratory tract infection among infants. RSV is a priority for vaccine development. In this study, we investigate the potential effectiveness of a two-vaccine strategy aimed at mothers-to-be, thereby boosting maternally acquired antibodies of infants, and their household cohabitants, further cocooning infants against infection. We use a dynamic RSV transmission model which captures transmission both within households and communities, adapted to the changing demographics and RSV seasonality of a low-income country. Model parameters were inferred from past RSV hospitalisations, and forecasts made over a 10-year horizon. We find that a 50% reduction in RSV hospitalisations is possible if the maternal vaccine effectiveness can achieve 75 days of additional protection for newborns combined with a 75% coverage of their birth household co-inhabitants (~7.5% population coverage).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.